We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?
Read MoreHide Full Article
Key Takeaways
MIRM's top line is led by Livmarli, with continued demand expected to support Q1 revenues.
Mirum's Livmarli posted $360 million in 2025 net sales, up 68.8% year over year.
MIRM expects 2026 net product sales of $630-$650 million from Livmarli and bile acid products.
Mirum Pharmaceuticals’ (MIRM - Free Report) top line is primarily being driven by its lead product, Livmarli (maralixibat), which has seen steady sales growth since its launch. The drug remains a key contributor to the company’s revenues.
Livmarli is an orally administered ileal bile acid transporter (“IBAT”) inhibitor currently approved worldwide for the treatment of cholestatic pruritus in patients with Alagille syndrome (“ALGS”). The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis (“PFIC”) in the United States and Europe.
The FDA has also approved a new tablet formulation of Livmarli for treating cholestatic pruritus in ALGS and PFIC patients, a move expected to improve convenience for older patients.
In 2025, Livmarli’s net product sales were $360 million, up 68.8% year over year. Building on this growing momentum, we expect investors to keep a close eye on Livmarli’s sales performance when Mirum reports its first-quarter 2026 results.
The continued demand for Livmarli is expected to drive MIRM’s top line in the first quarter.
The Zacks Consensus Estimate for Livmarli’s first-quarter sales stands at $105 million.
Besides Livmarli, Mirum is also making good progress with its other marketed products — Cholbam capsules and Ctexli tablets, which are approved for certain rare diseases. These products were added to Mirum’s commercial portfolio following the acquisition of Travere Therapeutics’ (TVTX - Free Report) bile acid products in 2023.
The acquisition of Travere Therapeutics’ bile acid products has diversified Mirum’s revenue stream. Sales from the bile acid products, comprising Cholbam and Ctexli tablets, also contributed meaningfully to MIRM’s top line in 2025.
Mirum expects worldwide net product sales of approximately $630-$650 million in 2026, reflecting strong Livmarli adoption and incremental sales from the bile acid products.
Meanwhile, Mirum’s lead pipeline candidate, volixibat, is currently being evaluated in two phase IIb studies for treating patients with primary biliary cholangitis (the VANTAGE study) and primary sclerosing cholangitis (the VISTAS study). The company recently initiated the phase II BLOOM study on its newly in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome, a rare genetic neurocognitive disorder.
MIRM’s Competition in the Target Market
Though Mirum is riding on the robust sales performance of Livmarli, the company’s heavy reliance on the drug for revenues remains a concern. Any regulatory setback for the drug in the days ahead could hurt the stock.
Competition is also rising from Albireo AB (now part of Ipsen), which markets Bylvay — an IBAT inhibitor directly competing with Livmarli in the PFIC and ALGS indications. Since both therapies work by inhibiting IBAT to lower serum bile acid levels, competition is likely to intensify and it could impact Mirum’s market share and revenue trajectory. Bylvay is considered the most direct competitor for Livmarli in the PFIC and ALGS markets.
Also, last month, GSK plc (GSK - Free Report) announced that the FDA has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).
Previously, GSK signed a license agreement with Italy-based Alfasigma, wherein the latter acquired exclusive global rights to develop and market Lynavoy for the given indication.
Though still in the early days, the FDA nod to Lynavoy is likely to pose stiff competition for Mirum’s volixibat.
MIRM’s Price Performance, Valuation and Estimates
Year to date, shares of Mirum have rallied 21.3% compared with the industry’s rise of 2.7%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Mirum is trading at a premium to the industry. Going by the price/book ratio, the company’s shares currently trade at 18.38, higher than 3.66 for the industry. The stock is also trading above its five-year mean of 7.37.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for its 2026 loss per share has widened from 6 cents to $1.77 over the past 60 days. During the same time frame, estimates for 2027 earnings per share have declined from 63 cents to 13 cents.
View the Zacks #1 Rank List
Image: Bigstock
Will Livmarli Continue to Aid Mirum's Top Line in Q1 Earnings?
Key Takeaways
Mirum Pharmaceuticals’ (MIRM - Free Report) top line is primarily being driven by its lead product, Livmarli (maralixibat), which has seen steady sales growth since its launch. The drug remains a key contributor to the company’s revenues.
Livmarli is an orally administered ileal bile acid transporter (“IBAT”) inhibitor currently approved worldwide for the treatment of cholestatic pruritus in patients with Alagille syndrome (“ALGS”). The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis (“PFIC”) in the United States and Europe.
The FDA has also approved a new tablet formulation of Livmarli for treating cholestatic pruritus in ALGS and PFIC patients, a move expected to improve convenience for older patients.
In 2025, Livmarli’s net product sales were $360 million, up 68.8% year over year. Building on this growing momentum, we expect investors to keep a close eye on Livmarli’s sales performance when Mirum reports its first-quarter 2026 results.
The continued demand for Livmarli is expected to drive MIRM’s top line in the first quarter.
The Zacks Consensus Estimate for Livmarli’s first-quarter sales stands at $105 million.
Besides Livmarli, Mirum is also making good progress with its other marketed products — Cholbam capsules and Ctexli tablets, which are approved for certain rare diseases. These products were added to Mirum’s commercial portfolio following the acquisition of Travere Therapeutics’ (TVTX - Free Report) bile acid products in 2023.
The acquisition of Travere Therapeutics’ bile acid products has diversified Mirum’s revenue stream. Sales from the bile acid products, comprising Cholbam and Ctexli tablets, also contributed meaningfully to MIRM’s top line in 2025.
Mirum expects worldwide net product sales of approximately $630-$650 million in 2026, reflecting strong Livmarli adoption and incremental sales from the bile acid products.
Meanwhile, Mirum’s lead pipeline candidate, volixibat, is currently being evaluated in two phase IIb studies for treating patients with primary biliary cholangitis (the VANTAGE study) and primary sclerosing cholangitis (the VISTAS study). The company recently initiated the phase II BLOOM study on its newly in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome, a rare genetic neurocognitive disorder.
MIRM’s Competition in the Target Market
Though Mirum is riding on the robust sales performance of Livmarli, the company’s heavy reliance on the drug for revenues remains a concern. Any regulatory setback for the drug in the days ahead could hurt the stock.
Competition is also rising from Albireo AB (now part of Ipsen), which markets Bylvay — an IBAT inhibitor directly competing with Livmarli in the PFIC and ALGS indications. Since both therapies work by inhibiting IBAT to lower serum bile acid levels, competition is likely to intensify and it could impact Mirum’s market share and revenue trajectory. Bylvay is considered the most direct competitor for Livmarli in the PFIC and ALGS markets.
Also, last month, GSK plc (GSK - Free Report) announced that the FDA has approved Lynavoy (linerixibat) for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).
Previously, GSK signed a license agreement with Italy-based Alfasigma, wherein the latter acquired exclusive global rights to develop and market Lynavoy for the given indication.
Though still in the early days, the FDA nod to Lynavoy is likely to pose stiff competition for Mirum’s volixibat.
MIRM’s Price Performance, Valuation and Estimates
Year to date, shares of Mirum have rallied 21.3% compared with the industry’s rise of 2.7%. The stock has also outperformed the sector and the S&P 500 during the same time frame, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Mirum is trading at a premium to the industry. Going by the price/book ratio, the company’s shares currently trade at 18.38, higher than 3.66 for the industry. The stock is also trading above its five-year mean of 7.37.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for its 2026 loss per share has widened from 6 cents to $1.77 over the past 60 days. During the same time frame, estimates for 2027 earnings per share have declined from 63 cents to 13 cents.
Image Source: Zacks Investment Research
MIRM's Zacks Rank
Mirum currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.